Triumvira Immunologics

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.

Triumvira Immunologics headquartered in United States, North America, operates in the Biotechnology, Health Care, Clinical Trials sector. The company focuses on Biotechnology and has secured $2.4B in funding across 24 round(s). With a team of 51-100 employees, Triumvira Immunologics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Triumvira Immunologics, raised $45.0M. Discover more about their projects, partnerships, and impact on our platform.